Nazartinib; EGF816; NVS-816

Nomen chemicum:

(R, E)-N-(7-chloro-1-(1-(4-(dimethylamino)sed-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)- 2-methylisonicotinamide

SMILES Code:

O=C(NC1=NC2=CC=CC(Cl)=C2N1[C@H]3CN(C(/C=C/CN(C)C)=O)CCCC3)C4=CC=NC(C)= C4

InChi Code:

InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33( 26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5; 8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1

InChi Key:

IOMMMLWIABWRKL-WUTDNEBXSA-N

Keyword:

Nazartinib, EGF816, EGF-816, EGF 816, NVS-816, 1508250-71-2.

Solubilitas:Solutum in DMSO

Repono:0 - 4° C pro brevi termino (dies ad hebdomades), vel -20° C ad terminum longum (menses)

Descriptio:

Nazartinib, etiam notus ut EGF816 et NVS-816, viva voce promptum est, irreversibile, tertium-generatio, factor incrementi epidermalis mutant-selectivam receptor (EGFR) inhibitor, cum actuositate antineoplastica potentiale. EGF816 covalenter adstringit et vetat actionem formarum mutantium EGFR, incluso T790M EGFR mutant, quo minus significat medium EGFR mediatum. Hoc potest utrumque cellam mortem inducere et incrementum tumoris inhibere in cellulis tumoris EGFR-exprimentibus. EGF816 potius vetat formas mutatas EGFR inclusas T790M, mutationem resistentiae secundario acquisitas, et in tumoribus cum resistentia mediata cum T790M-medicata beneficia habere potest cum aliis inhibitoribus EGFR tyrosinum kinasum comparatum.

Target: EGFR